tiprankstipranks
Trending News
More News >
KYORIN Pharmaceutical Co.,Ltd. (JP:4569)
:4569
Japanese Market
Advertisement

KYORIN Pharmaceutical Co.,Ltd. (4569) Price & Analysis

Compare
2 Followers

4569 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

6.46%90.04%
Insiders
6.46%
Mutual Funds
― Other Institutional Investors
90.04% Public Companies and
Individual Investors

4569 FAQ

What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1331.00 and its highest was ¥1751.00 in the past 12 months.
    What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
    KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥78.85B.
      When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
      KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is Jul 31, 2025 which is in 12 days.
        How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
        Currently, no data Available
        Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
        According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
          KYORIN Pharmaceutical Co.,Ltd. pays a Annually dividend of ¥57 which represents an annual dividend yield of 0.67%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
            What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
            KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
            KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
              What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
              Currently, no hedge funds are holding shares in JP:4569

              Company Description

              KYORIN Pharmaceutical Co.,Ltd.

              KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
              Similar Stocks
              Company
              Price & Change
              Follow
              Kissei Pharmaceutical Co
              Torii Pharmaceutical Co
              Towa Pharmaceutical Co
              Mochida Pharmaceutical Co., Ltd.
              ASKA Pharmaceutical Holdings Co., Ltd.
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis